SS-31 (elamipretide)
Cell-permeable aromatic-cationic tetrapeptide that targets the inner mitochondrial membrane, used in mitochondrial research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-SS31-10 · ≥99% (see COA) · Lyophilised powder
Note: Salt form (e.g. acetate or TFA) and net peptide content to be confirmed from the supplier COA. Elamipretide holds a non-UK regulatory approval [TO VERIFY against supplier COA]; the client's solicitor has advised that it holds no UK marketing authorisation.
SS-31 (elamipretide) overview
SS-31 (Szeto-Schiller peptide 31; INN elamipretide) is a synthetic tetrapeptide containing D-arginine and 2′,6′-dimethyltyrosine. It is supplied as a lyophilised solid for in-vitro laboratory research.
SS-31 (elamipretide) research background
Evidence status: Findings summarised here include clinical-trial data; this compound has a regulatory status as a medicine in some countries outside the UK, which does not apply to this research-grade product. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- SS-31 (elamipretide, D-Arg-Dmt-Lys-Phe-NH₂) is a Szeto–Schiller tetrapeptide that targets the inner mitochondrial membrane [1][2]. In September 2025 it received accelerated approval in the US for Barth syndrome [3]. It does not have a UK marketing authorisation, and this research-grade product is not a medicine.
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
Research areas & model types
Human clinical research status
Safety observations reported in studies
- In MMPOWER-3 it was reported as generally well tolerated [5].
Known limitations
- Results are mixed across indications [5].
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- Researchers have proposed cardiolipin-targeting as a strategy across mitochondrial diseases [2].
Registered clinical studies (ongoing or unpublished)
- NCT06373731 — Phase 3 ReNEW trial in dry age-related macular degeneration (sponsor: Stealth BioTherapeutics). Listed as active, not recruiting.
- NCT07275424 — Phase 2a study in healthy older adults. Listed as recruiting.
- NCT07531251 — Phase 3b/4 study in Barth syndrome (sponsor: Stealth BioTherapeutics). Listed as recruiting.
Registry entries checked on ClinicalTrials.gov on 24 October 2026; status as listed by the sponsor. Registration does not imply results or efficacy.
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 2006. PubMed 16796378 · doi:10.1007/BF02854898
- Tung C, Varzideh F, Farroni E et al.. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci. 2025. PubMed 39940712 · doi:10.3390/ijms26030944
- Shirley M. Elamipretide: First Approval. Drugs. 2026. PubMed 41335372 · doi:10.1007/s40265-025-02269-8
- Birk AV, Liu S, Soong Y et al.. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013. PubMed 23813215 · doi:10.1681/ASN.2012121216
- Karaa A, Bertini E, Carelli V et al.. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023. PubMed 37268435 · doi:10.1212/WNL.0000000000207402
- Thompson WR, Manuel R, Abbruscato A et al.. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024. PubMed 38602181 · doi:10.1016/j.gim.2024.101138
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
Browse similar compounds: Mitochondrial & metabolic biochemistry research compounds or the full catalogue.